NeoGenomics, Inc. (NEO)
USD 9.64
(0.78%)
USD 9.64
(0.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -107.73 Million USD | 29.63% |
| 2022 | -153.1 Million USD | -1432.14% |
| 2021 | -9.99 Million USD | -368.93% |
| 2020 | -2.13 Million USD | -125.44% |
| 2019 | 8.37 Million USD | -16.57% |
| 2018 | 10.04 Million USD | 196.87% |
| 2017 | 3.38 Million USD | 31.39% |
| 2016 | 2.57 Million USD | 145.68% |
| 2015 | -5.63 Million USD | -354.06% |
| 2014 | 2.21 Million USD | -30.12% |
| 2013 | 3.17 Million USD | 162.1% |
| 2012 | 1.21 Million USD | 396.09% |
| 2011 | -409 Thousand USD | 86.2% |
| 2010 | -2.96 Million USD | -71.52% |
| 2009 | -1.72 Million USD | -95.42% |
| 2008 | -883.98 Thousand USD | 71.86% |
| 2007 | -3.14 Million USD | -2343.65% |
| 2006 | 139.99 Thousand USD | 117.49% |
| 2005 | -800.36 Thousand USD | -9.7% |
| 2004 | -729.56 Thousand USD | -47.59% |
| 2003 | -494.33 Thousand USD | 15.31% |
| 2002 | -583.67 Thousand USD | 92.77% |
| 2001 | -8.07 Million USD | -731.99% |
| 2000 | -970.92 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -20.39 Million USD | 27.59% |
| 2024 Q3 | -21.19 Million USD | -3.92% |
| 2024 Q1 | -28.16 Million USD | -51.66% |
| 2023 Q3 | -24.19 Million USD | 19.06% |
| 2023 Q4 | -18.57 Million USD | 23.23% |
| 2023 FY | -107.73 Million USD | 29.63% |
| 2023 Q1 | -30.38 Million USD | -22.3% |
| 2023 Q2 | -29.89 Million USD | 1.63% |
| 2022 Q3 | -39.51 Million USD | 0.48% |
| 2022 Q1 | -52.02 Million USD | -25.17% |
| 2022 Q4 | -24.84 Million USD | 37.11% |
| 2022 FY | -153.1 Million USD | -1432.14% |
| 2022 Q2 | -39.7 Million USD | 23.69% |
| 2021 Q1 | -15.1 Million USD | -372.74% |
| 2021 Q2 | -22.36 Million USD | -48.06% |
| 2021 Q4 | -41.56 Million USD | -4.67% |
| 2021 FY | -9.99 Million USD | -368.93% |
| 2021 Q3 | -39.71 Million USD | -77.55% |
| 2020 Q4 | 5.53 Million USD | 18.63% |
| 2020 Q2 | -18.9 Million USD | -257.21% |
| 2020 Q1 | -5.29 Million USD | -328.05% |
| 2020 FY | -2.13 Million USD | -125.44% |
| 2020 Q3 | 4.66 Million USD | 124.69% |
| 2019 Q4 | 2.32 Million USD | -36.57% |
| 2019 Q3 | 3.65 Million USD | -18.29% |
| 2019 Q2 | 4.47 Million USD | 75.75% |
| 2019 Q1 | 2.54 Million USD | -9.68% |
| 2019 FY | 8.37 Million USD | -16.57% |
| 2018 Q1 | 2.5 Million USD | -44.17% |
| 2018 Q2 | 794 Thousand USD | -68.3% |
| 2018 Q3 | 3.92 Million USD | 393.7% |
| 2018 Q4 | 2.82 Million USD | -28.04% |
| 2018 FY | 10.04 Million USD | 196.87% |
| 2017 Q3 | -2.3 Million USD | -275.34% |
| 2017 FY | 3.38 Million USD | 31.39% |
| 2017 Q4 | 4.48 Million USD | 294.75% |
| 2017 Q2 | 1.31 Million USD | 1242.61% |
| 2017 Q1 | -115 Thousand USD | 96.08% |
| 2016 Q3 | 1.39 Million USD | -36.39% |
| 2016 FY | 2.57 Million USD | 145.68% |
| 2016 Q1 | 1.92 Million USD | 136.86% |
| 2016 Q2 | 2.19 Million USD | 14.1% |
| 2016 Q4 | -2.93 Million USD | -310.39% |
| 2015 Q1 | -561 Thousand USD | -142.53% |
| 2015 Q4 | -5.21 Million USD | -4674.56% |
| 2015 Q3 | 114 Thousand USD | 307.14% |
| 2015 FY | -5.63 Million USD | -354.06% |
| 2015 Q2 | 28 Thousand USD | 104.99% |
| 2014 Q4 | 1.31 Million USD | 1906.85% |
| 2014 FY | 2.21 Million USD | -30.12% |
| 2014 Q1 | 394 Thousand USD | -67.28% |
| 2014 Q2 | 578 Thousand USD | 46.7% |
| 2014 Q3 | -73 Thousand USD | -112.63% |
| 2013 Q3 | 1.16 Million USD | 129.7% |
| 2013 Q2 | 505 Thousand USD | 65.57% |
| 2013 Q1 | 305 Thousand USD | 55.61% |
| 2013 FY | 3.17 Million USD | 162.1% |
| 2013 Q4 | 1.2 Million USD | 3.79% |
| 2012 Q1 | 861 Thousand USD | 129.6% |
| 2012 FY | 1.21 Million USD | 396.09% |
| 2012 Q4 | 196 Thousand USD | 128.65% |
| 2012 Q2 | 839 Thousand USD | -2.56% |
| 2012 Q3 | -684 Thousand USD | -181.53% |
| 2011 Q2 | -114 Thousand USD | 83.97% |
| 2011 FY | -409 Thousand USD | 86.2% |
| 2011 Q3 | 42 Thousand USD | 136.84% |
| 2011 Q4 | 375 Thousand USD | 792.86% |
| 2011 Q1 | -711 Thousand USD | -26.29% |
| 2010 Q4 | -563 Thousand USD | 44.37% |
| 2010 FY | -2.96 Million USD | -71.52% |
| 2010 Q3 | -1.01 Million USD | -26.98% |
| 2010 Q1 | -591 Thousand USD | 57.41% |
| 2010 Q2 | -797 Thousand USD | -34.86% |
| 2009 FY | -1.72 Million USD | -95.42% |
| 2009 Q3 | -626.42 Thousand USD | -552.25% |
| 2009 Q4 | -1.38 Million USD | -121.51% |
| 2009 Q1 | 147.99 Thousand USD | 121.29% |
| 2009 Q2 | 138.51 Thousand USD | -6.41% |
| 2008 Q2 | 141.52 Thousand USD | 167.31% |
| 2008 FY | -883.98 Thousand USD | 71.86% |
| 2008 Q4 | -695.11 Thousand USD | -478.64% |
| 2008 Q3 | -120.13 Thousand USD | -184.88% |
| 2008 Q1 | -210.26 Thousand USD | 86.54% |
| 2007 Q1 | -219.54 Thousand USD | 43.88% |
| 2007 Q3 | -576.93 Thousand USD | 34.51% |
| 2007 Q4 | -1.56 Million USD | -170.82% |
| 2007 FY | -3.14 Million USD | -2343.65% |
| 2007 Q2 | -880.94 Thousand USD | -301.26% |
| 2006 Q4 | -391.22 Thousand USD | -439.23% |
| 2006 FY | 139.99 Thousand USD | 117.49% |
| 2006 Q3 | 115.32 Thousand USD | -51.86% |
| 2006 Q2 | 239.57 Thousand USD | 35.88% |
| 2006 Q1 | 176.31 Thousand USD | 157.86% |
| 2005 FY | -800.36 Thousand USD | -9.7% |
| 2005 Q1 | -187.99 Thousand USD | 34.54% |
| 2005 Q4 | -304.74 Thousand USD | -70.92% |
| 2005 Q3 | -178.29 Thousand USD | -37.86% |
| 2005 Q2 | -129.33 Thousand USD | 31.2% |
| 2004 Q3 | -148 Thousand USD | -1.73% |
| 2004 Q2 | -145.49 Thousand USD | 2.28% |
| 2004 FY | -729.56 Thousand USD | -47.59% |
| 2004 Q1 | -148.89 Thousand USD | -15.97% |
| 2004 Q4 | -287.17 Thousand USD | -94.03% |
| 2003 Q1 | -110.53 Thousand USD | -107.55% |
| 2003 Q4 | -128.38 Thousand USD | -2.24% |
| 2003 FY | -494.33 Thousand USD | 15.31% |
| 2003 Q3 | -125.56 Thousand USD | 3.29% |
| 2003 Q2 | -129.84 Thousand USD | -17.46% |
| 2002 Q4 | 1.46 Million USD | 300.33% |
| 2002 Q1 | -580.84 Thousand USD | 91.97% |
| 2002 Q3 | -731.28 Thousand USD | -240.72% |
| 2002 FY | -583.67 Thousand USD | 92.77% |
| 2002 Q2 | -214.63 Thousand USD | 63.05% |
| 2001 Q2 | -214.59 Thousand USD | 37.77% |
| 2001 Q4 | -7.22 Million USD | -2398.48% |
| 2001 Q1 | -344.81 Thousand USD | 22.58% |
| 2001 Q3 | -289.34 Thousand USD | -34.83% |
| 2001 FY | -8.07 Million USD | -731.99% |
| 2000 Q2 | -216.97 Thousand USD | -30.5% |
| 2000 Q3 | -142.29 Thousand USD | 34.42% |
| 2000 Q4 | -445.37 Thousand USD | -212.99% |
| 2000 FY | -970.92 Thousand USD | 0.0% |
| 2000 Q1 | -166.27 Thousand USD | 0.0% |
| 1999 Q1 | -99.04 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -10.661% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -883.595% |
| Aspira Women's Health Inc. | -18.85 Million USD | -471.483% |
| Biodesix, Inc. | -41.34 Million USD | -160.597% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -4053.937% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1251.222% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1251.222% |
| Bionano Genomics, Inc. | -215.24 Million USD | 49.947% |
| CareDx, Inc | -101.9 Million USD | -5.727% |
| Check-Cap Ltd. | -19.28 Million USD | -458.594% |
| Castle Biosciences, Inc. | -67.97 Million USD | -58.489% |
| DarioHealth Corp. | -56.18 Million USD | -91.739% |
| Exact Sciences Corporation | -215.01 Million USD | 49.893% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -48.203% |
| Guardant Health, Inc. | -564.72 Million USD | 80.922% |
| ICON Public Limited Company | 956.15 Million USD | 111.268% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 109.82% |
| Illumina, Inc. | -1.06 Billion USD | 89.922% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -947.692% |
| iSpecimen Inc. | -11.16 Million USD | -864.568% |
| Standard BioTools Inc. | -76.6 Million USD | -40.648% |
| MDxHealth SA | -27.32 Million USD | -294.247% |
| 23andMe Holding Co. | -321.35 Million USD | 66.475% |
| Medpace Holdings, Inc. | 336.82 Million USD | 131.986% |
| Myriad Genetics, Inc. | -123.7 Million USD | 12.905% |
| Mainz Biomed B.V. | -26.64 Million USD | -304.343% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -924.035% |
| Neogen Corporation | 58.66 Million USD | 283.652% |
| Inotiv, Inc. | -81.46 Million USD | -32.256% |
| Natera, Inc. | -446.24 Million USD | 75.857% |
| OpGen, Inc. | -15.68 Million USD | -586.721% |
| OPKO Health, Inc. | -157.02 Million USD | 31.388% |
| Psychemedics Corporation | -2.92 Million USD | -3588.326% |
| Prenetics Global Limited | -52.51 Million USD | -105.158% |
| Prenetics Global Limited | -52.51 Million USD | -105.158% |
| Precipio, Inc. | -7.62 Million USD | -1313.858% |
| Personalis, Inc. | -109.93 Million USD | 2.001% |
| RadNet, Inc. | 98.69 Million USD | 209.158% |
| Sera Prognostics, Inc. | -39.82 Million USD | -170.551% |
| Sotera Health Company | 276.69 Million USD | 138.937% |
| Neuronetics, Inc. | -30.55 Million USD | -252.608% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -2378.969% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -2378.969% |
| Trinity Biotech plc | -27.04 Million USD | -298.358% |
| T2 Biosystems, Inc. | -49.66 Million USD | -116.93% |
| Twist Bioscience Corporation | -220.83 Million USD | 51.213% |
| Exagen Inc. | -22.83 Million USD | -371.761% |